List view / Grid view
21 March 2014 | By The European Medicines Agency
Entyvio (vedolizumab) offers a treatment option for patients who do not respond to standard therapies...
21 March 2014 | By METTLER TOLEDO
Take the worry out of weighing with new balances designed to aid compliance and process security...
20 March 2014 | By AbbVie
AbbVie announced the initiation of a pivotal Phase 3 clinical trial that will evaluate the use of HUMIRA® (adalimumab)...
20 March 2014 | By Johnson & Johnson
Independent data monitoring committee recommends halting trial and unblinding data based on treatment efficacy...
20 March 2014 | By Novartis
Novartis has announced the launch of the Lucentis® (ranibizumab) pre-filled syringe in Germany, with other markets to follow throughout 2014...
20 March 2014 | By GlaxoSmithKline
GSK will continue the trial in order to assess the third co-primary endpoint, which is disease-free survival in a gene signature positive sub-population...
20 March 2014 | By AstraZeneca
AstraZeneca announced that Ann Cairns will be proposed to shareholders for election as a Non-Executive Director at the Company’s Annual General Meeting on 24 April 2014...
20 March 2014 | By Pfizer Inc.
Pfizer intends to submit biologics license application for bivalent rLP2086 to U.S. Food and Drug Administration by mid-2014...
19 March 2014 | By Janssen
Additional Phase 3 data from the QUEST-1, QUEST-2 and PROMISE studies explore potential of simeprevir in genotype 1 hepatitis C patients while new ATTAIN data demonstrate a superior safety profile for simeprevir...
19 March 2014 | By The European Medicines Agency
The European Medicines Agency has published its work programme for 2014...
19 March 2014 | By Sanofi
A long-term strategic business collaboration to co-develop and commercialize an innovative vaccine against pneumococcal infection to address global public-health needs...
19 March 2014 | By Pfizer Inc
Pfizer Inc. announced the launch of its fourth integrated annual review, which summarizes the company’s 2013 financial, environmental and social responsibility performance...
19 March 2014 | By Daiichi Sankyo Company
Astellas Pharma Inc. and Daiichi Sankyo Company, Limited announced the companies would form a compound library sharing partnership for approximately 400,000 selected compounds...
18 March 2014 | By Biogen Idec
Biogen Idec announced that the U.S. Food and Drug Administration has extended the initial Prescription Drug User Fee Act date for its review of the Biologics License Application for marketing approval of PLEGRIDY...
18 March 2014 | By Astellas
Roxadustat could change treatment of anaemia associated with CKD and remove the need for multiple injections...
